


Journal Pre-proof

Factors affecting stability and infectivity of SARS-CoV-2

Kwok-Hung Chan, Siddharth Sridhar, Ricky Ruiqi Zhang, Hin Chu, Agnes Yim-Fong Fung, Gabriella Chan, Jasper Fuk-Woo Chan, Kelvin Kai-Wang To, Ivan Fan-Ngai Hung, Vincent Chi-Chung Cheng, Kwok-Yung Yuen



PII: S0195-6701(20)30339-X

DOI: <https://doi.org/10.1016/j.jhin.2020.07.009>

Reference: YJHIN 6098

To appear in: *Journal of Hospital Infection*

Received Date: 21 April 2020

Accepted Date: 6 July 2020

Please cite this article as: Chan K-H, Sridhar S, Zhang RR, Chu H, Fung AY-F, Chan G, Chan JF-W, To KK-W, Hung IF-N, Cheng VC-C, Yuen K-Y, Factors affecting stability and infectivity of SARS-CoV-2, *Journal of Hospital Infection*, <https://doi.org/10.1016/j.jhin.2020.07.009>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd on behalf of The Healthcare Infection Society.

Factors affecting stability and infectivity of SARS-CoV-2

Kwok-Hung Chan^{a,d,e,*#}, Siddharth Sridhar^{a,d,e*}, Ricky Ruiqi Zhang^{ab*}, Hin Chu^{a,d,e}, Agnes Yim-Fong Fung^a, Gabriella Chan^a, Jasper Fuk-Woo Chan^{a,d,e}, Kelvin Kai-Wang To^{a,d,e}, Ivan Fan-Ngai Hung^{b,d,e}, Vincent Chi-Chung Cheng^c and Kwok-Yung Yuen^{a,d,e,#}

^aDepartment of Microbiology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, People's Republic of China

^bDepartment of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, People's Republic of China

^cDepartment of Microbiology, Queen Mary Hospital, Hospital Authority, Hong Kong Special Administrative Region, China.

^dState Key Laboratory for Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, People's Republic of China

^eCarol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, People's Republic of China

Keywords: SARS-CoV-2, stability, infectivity, high infection rate, route of transmission

* Contributed equally to this work

#Corresponding authors: Kwok-Yung Yuen , kyyuen@hku.hk and Kwok-Hung Chan, chankh2@hku.hk

23 Summary

24 Background

25 In late 2019, a novel human coronavirus, SARS-CoV-2, emerged in Wuhan, China. This virus
26 has caused a global pandemic involving more than 200 countries. SARS-CoV-2 is highly
27 adapted to humans and readily transmits from person-to-person.

28

29 Aim

30 The aim of this study was to investigate the infectivity of SARS-CoV-2 under various
31 environmental factors, disinfectants and different pH conditions. The efficacy of a variety of
32 laboratory virus inactivation methods and home disinfectants against SARS-CoV-2 were
33 investigated.

34

35 Methods

36 The residual virus in dried form or in solution was titrated on Vero E6 cell line at day 0, 1, 3,
37 5, and 7 after incubation at different temperatures. The viability of virus was determined after
38 treatment with different disinfectants and pH solutions at room temperature (20~25°C).

39

40 Findings

41 SARS-CoV-2 was able to retain viability for 3-5 days in dried form or 7 days in solution at
42 room temperature. SARS-CoV-2 could be detected under a wide range of pH conditions from
43 pH4 to pH11 for several days and 1 to 2 days in stool at room temperature but lost 5 logs of

44 infectivity. A variety of commonly used disinfectants and laboratory inactivation procedures
45 were found to reduce viral viability effectively.

46

47 Conclusion

48 This study demonstrates the stability of SARS-CoV-2 on environmental surfaces and raises
49 the possibility of faecal-oral transmission. Commonly used fixatives, nucleic acid extraction
50 methods and heat inactivation were found to significantly reduce viral infectivity that could
51 ensure hospital and laboratory safety during the COVID-19 pandemic.

52

53

54

55 Introduction

56 The first human coronavirus of confirmed zoonotic origin, SARS-CoV-1, rose in 2003. It
57 spread in over 30 countries and caused severe acute respiratory syndrome (SARS) [1]. Sixteen
58 years later, coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. COVID-19 is
59 caused by another zoonotic coronavirus: SARS-CoV-2 [2, 3]. SARS-CoV-2 belongs to the
60 beta-coronavirus lineage B and shares ~ 80% identity to SARS-CoV-1. SARS-CoV-2 is
61 currently causing a global pandemic which, as of mid-April 2020, has affected more than 2
62 million people and killed more than 150,000 people [4]. The actual number of infected cases is
63 believed to be higher due to limitation of testing to persons requiring hospitalization in several
64 countries during the early stages of the pandemic. It is estimated that 18% of infections are
65 asymptomatic [5]. According to current estimates, the case fatality rate of COVID-19
66 infection is lower than that of SARS. However, due to its propensity to cause milder
67 infections, SARS-CoV-2 spreads more efficiently in communities in the absence of rigorous
68 social distancing measures. Previous findings showed that the viability of SARS-CoV-1
69 degraded and was rapidly lost at higher temperatures and higher relative humidity [6]. This
70 may have impaired its transmission in tropical areas such as Malaysia, Indonesia or Thailand.
71 Judging by the rapidity of its spread, SARS-CoV-2 infection appears less affected by hot
72 weather and high humidity prevailing in Asian countries including Malaysia, Thailand and
73 Singapore [4]. However, it is notable that their SARS-CoV-2 incidence rate appears lower
74 than countries in Europe or USA [4].

75

76 Understanding the viability of SARS-CoV-2 in various environmental conditions and the
77 effectiveness of disinfectants against it is crucial. This is particularly relevant to hospital
78 settings, where highly effective viral inactivation methods are required in wards nursing

79 COVID-19 patients and laboratories processing samples from COVID-19 patients. In this
80 study, stability of SARS-CoV-2 under various environmental factors and pH conditions were
81 tested. We also investigated the effect of various disinfectant solutions and laboratory
82 inactivation methods on SARS-CoV-2 viability. These factors could play a major role in
83 transmission of disease and might suggest methods to stop the spread of the virus.

84

85

Journal Pre-proof

86 Materials and methods

87 1. Virus strains and cell line.

88 Vero E6 cell line was cultured in minimal essential medium (MEM, Gibco, USA) with 10%
89 fetal bovine serum (FBS, Gibco, USA), penicillin and streptomycin (Gibco, USA). Virus
90 strains used in the study were SARS-CoV-2 HKU-SZ-005b and SARS-CoV-1 HKU39849
91 [6,7]. Virus propagated in Vero E6 was maintained in MEM with 1% FBS, and was stored at -
92 80°C until use.

93

94 2. The Median Tissue Culture Infectious Dose (TCID₅₀) assay.

95 Confluent Vero E6 cells on 96-well plates were incubated with 100 µl of serial 10-fold
96 dilutions of virus in MEM containing 1% FBS for 1 hour at 37°C. Then, the virus was
97 removed from 96-well plates and 100ul of fresh MEM with 1% FBS was added to the cells.
98 After the change of medium, cells infected with SARS-CoV-2 underwent an incubation of 5
99 days, while SARS-CoV-1 infected cells underwent a 3-day incubation, and cytopathic effect
100 (CPE) was recorded. TCID₅₀ was determined by the Reed and Muench method [8].

101

102 3. Effect of drying and heat.

103 Ten µl of virus (SARS-CoV-2, 10^{6.5}TCID₅₀/ml; SARS-CoV-1, 10⁷TCID₅₀/ml) was placed on
104 a glass slide within a shell vial, kept at room temperature (20~25°C and relative humidity of
105 63%) and allowed to dry according to our previous study with slight modifications (6). One
106 hundred microliters of MEM were used to re-suspend the virus for 0, 1, 3, 5, and 7 days after
107 incubation at different temperatures: refrigerator (4°C), room temperature (25°C) and two
108 incubators with different temperatures (33°C and 37°C). All the time points were set up in

109 triplicate and was undertaken in the dark. The residual virus infectivity was titrated (8).
110 Controls were viruses in solution, and stored in closed screw cap tubes with similar treatment.

111

112 4. Effect of pH on viability

113 Viral transport medium with different pH from 2 to 13 using 5M and 1M HCl or 5N and 1N
114 NaOH were prepared as described (9). One hundred microliters of SARS-CoV-2 with
115 $10^{6.5}$ TCID₅₀/ml was added into each bottles of 0.9 ml VTM and incubated at room temperature
116 (20-25°C). All the tests were done in triplicates. The viability of virus was tested on day 1,
117 day 3 and day 6. On each testing day, the pH of the VTM bottles were neutralized to pH 7 and
118 viral titre was measured using the TCID₅₀ assay (8). An untreated virus stock solution as the
119 viral load for the positive control was included.

120

121 5. Stability in stool

122 One hundred microliters of virus with $10^{6.5}$ TCID₅₀/ml was added to 0.9 ml watery stool
123 derived from a human patient (10). Antibiotics (Vancomycin 100 µg/ml, Amikacin 90
124 µg/ml and nystatin 40 units/ml) were added to suppress any potential bacterial or fungal
125 growth. The experiment was set up in duplicates. The viability of the virus was titrated as
126 described above [8]. An untreated virus stock solution as the viral load for the positive control
127 was included.

128

129 6. Stability in disinfectants

130 Thirty microlitres of SARS-CoV-2 ($10^{6.5}$ TCID₅₀/ml) and 270 µl of various disinfectants were
131 mixed and incubated at room temperature (Table 1). After incubation for 1 minute and 5

132 minutes at room temperature (20~25°C), 900 µl of MEM with 1% FBS was added in 100 µl of
133 virus-disinfectant mixture to dilute the disinfectants effect immediately before determination
134 of residual virus infectivity by the TCID₅₀ assay as described [8]. All disinfectants without
135 virus was titrated in parallel to determine the cytotoxicity effect. An untreated virus stock
136 solution as the viral load for the positive control was also included.

137

138 7. Heat inactivation of SARS-CoV-2

139 Thirty microlitres of SARS-CoV-2 ($10^{5.5}$ TCID₅₀/ml) and 270 µl of FBS were mixed and
140 incubated at 56°C for 30min. then, the residual infectivity of the virus was determined by
141 TCID₅₀ assay as described above. The test was set up in triplicates.

142

143

144 8. Viability after fixation treatment

145 Vero E6 cells were infected with SARS-CoV-2 at one multiplicity of infection (MOI) in a 6
146 well-plate for two days. The infected cells were scraped, spotted on slides and dried. The fixed
147 smears were fixed with chilled acetone (VWR Chemicals BDH, USA) for 10 minutes at -20°C
148 or 4% paraformaldehyde for 30 minutes at room temperature. The dried acetone and
149 paraformaldehyde fixed smears were washed twice in PBS to remove residual fixatives. The
150 inactivation effects of these fixative were monitored by scraping cells from fixed smears onto
151 culture tube with VeroE6 cells. Cytopathic effect was examined up to 7 days and then antigen
152 expression of NP of COVID-19 was tested [11].

153

154 Results

155 Dried SARS-CoV-2 retained viability for 3~ 5 days at room temperature (20 ~25°C) with
156 prolonged survival for more than 14 days at 4°C (Fig 1). The virus lost its infectivity within 1
157 day at warmer temperatures (~37°C). SARS-CoV-2 in solution retained viability for 7 days at
158 room temperature (20~25°C) and remained viable up to 14 days at 4°C. The virus suspended
159 in solution retained viability for 1~2 days at hot temperature 33~37°C. In comparison, SARS-
160 CoV-1 had similar viability as SARS-CoV-2 at the same environmental conditions except that
161 dried SARS-CoV-1 had better survival rates for 7 to 14 days at room temperature (20~25°C).

162

163 When SARS-CoV-2 was added in VTM with pH ranging from 2 to 13, the virus remained
164 viable up to 6 days but lost between 2.9 and 5.33 logs of infectivity from pH5 to pH9 and up
165 to 1~2 days in pH4 and pH11 (Table 2). The virus lost infectivity within 1 day at pH extremes
166 (pH2~3 and pH11~12). The virus lost 5.25 logs of infectivity in stool over a 3-day period.

167

168 Laboratory or domestic disinfectants, including two commonly used as a lysis buffer for
169 nucleic acid extraction, were tested for their effects on SARS-COV-2 on Vero E6 (Table 3).
170 Due to the cytotoxicity of certain disinfectants, detection limit of inactivation had been found
171 to range from 0.83 to 3.25 log₁₀ reduction for 1 minute and 0.92 to 3.75 log₁₀ reduction for 5
172 minutes. This showed that SARS-CoV-2, like SARS-CoV-1, can be inactivated by common
173 laboratory or domestic disinfectants [10, 12, 13].

174

175 When the virus was added to 90% FBS or MEM and was heated at 56°C for 30 minutes, virus
176 viability in both FBS and MEM was reduced by at least 3 logs (3.58±0.29). This mimics the

177 conditions of heat inactivation, which should effectively inactivate SARS-CoV-2 in human
178 serum for use in immunoassays.

179

180 After treatment with chilled acetone or 4% paraformaldehyde, the viability of fixed culture
181 cells was tested. No CPE was observed or virus was detected by NP antigen expression. As
182 for SARS-CoV-1, chilled acetone is required to complete inactivation of SARS-CoV-2
183 infected cell smears [10]. In this study, both chilled acetone and 4% paraformaldehyde
184 completely inactivated SARS-CoV-2, rendering fixed slides safe for further processing in a
185 Biosafety Level 2 laboratory.

186

187

188 Discussion

189 The main transmission routes of SARS-CoV-2 are believed to be via (1) inhaling aerosols
190 generated by infected persons, (2) direct contact with infected persons and, (3) contact with
191 environmental fomites [13, 14]. Our study investigates infectiousness of the virus under a
192 variety of environmental conditions. In this study, the dynamic rate of decay of SARS-CoV-2
193 was similar to SARS-CoV-1 (Fig 1). Dried SARS-CoV-2 virus on glass can retain viability for
194 over 3~4 days at room temperature (22–25°C) and 14 days at cold temperature (4°C), but
195 loses viability rapidly within one day at warm temperatures (37°C). However, SARS-CoV-2
196 in solution remained viable for longer under the same different temperature conditions
197 compared with dried SARS-CoV-2. Our data demonstrated that SARS-CoV-2 could survive
198 on environmental surfaces and that such contaminated surfaces may act as a reservoir for
199 transmission of this virus if not adequately cleaned and disinfected.

200

201 These could explain large SARS-CoV-2 outbreaks such as the one on the Diamond Princess
202 cruise ship. This outbreak caused 712 out of 3711 passengers to become infected with 12
203 deaths. This ship had been placed under quarantine orders from 5 February 2020 [5]. All
204 passengers were confined in the ship with close contact during the quarantine period and
205 shared common food and facilities such as buffet, water supply, shared sanitation and air-
206 conditioning systems for many days. SARS-CoV-2 has been shown to have a longer half-life
207 on stainless steel and plastic surfaces [14]. SARS-CoV-2 outbreaks also occurred in military
208 warships in USA and France. Our study clearly illustrates how SARS-CoV-2 can cause long
209 lasting environmental contamination in such settings.

210

211 In this study, we have demonstrated that SARS-CoV-2, like SARS-CoV-1, can survive in
212 stool for up to 1 to 2 days but with a 5-log loss of viability [10]. This suggests that the viability
213 is quickly lost in faecal material. SARS-CoV-2 is frequently shed in the stool of infected
214 patients [15]. Due to the virus remaining viable under a wide range of pH and environmental
215 conditions, we anticipate that it would be able to retain its infectivity in environmental
216 surfaces and potentially even in infected food handlers shedding SARS-CoV-2 in faeces.
217 Transmission via the faecal-oral route is theoretically possible, especially in individuals with
218 reduced gastric acidity due to medications like proton pump inhibitors. In fact, the SARS-
219 CoV-2 host receptor was found in the cytoplasm of gastrointestinal epithelia cells of infected
220 patients [15] and 17.6% of patients with COVID-19 had gastrointestinal symptoms and virus
221 RNA was detected in stool samples from 48.1% patients [16].

222

223 In this study, the results showed that a variety of commonly used disinfectants and laboratory
224 inactivation procedures can reduce viral viability. This is particularly significant for healthcare
225 settings including laboratories that require highly reliable inactivation methods to safeguard
226 staff working with COVID-19 patients and samples. PCR assays, immunofluorescence
227 staining and serology are all core components of the BSL-2 virology laboratory. Our study has
228 confirmed that commonly used fixatives, nucleic acid extraction methods and heat inactivation
229 can significantly abrogate viral infectivity. This study, therefore, has a direct impact on
230 hospital and laboratory safety during the COVID-19 pandemic.

231

232 A limitation of our study is that residual cytotoxicity from disinfectants might have been
233 present as we performed dilution rather than neutralization of active compounds before virus
234 titration.

235

236 Conclusion

237 Our data presented here contribute to a better understanding of the stability of SARS-CoV-2 in
238 different environmental situations. The stability of SARS-CoV-2 is similar to SARS-CoV-1.
239 This study showed that SARS-CoV-2 can survive for days on contaminated environmental
240 surfaces and for prolonged periods of time when in fluid suspensions. This has implication for
241 infection transmission in healthcare, but also in terms of transmission related to food handlers
242 and workers in meat and poultry processing facilities [17]. Finally, we show that commonly
243 used viral inactivation methods in the clinical virology laboratory and disinfectant solutions
244 used in healthcare settings are sufficient to drastically reduce viability of SARS-CoV-2, as a
245 contribution to improve hospital safety

246

247

248 Conflict of Interests

249 None declared

250

251 Funding Source

252 This study was partly supported by the donations of May Tam Mak Mei Yin, Richard Yu and
253 Carol Yu, the Shaw Foundation Hong Kong, Michael Seak-Kan Tong, Respiratory Viral
254 Research Foundation Limited, Hui Ming, Hui Hoy and Chow Sin Lan Charity Fund Limited,
255 Chan Yin Chuen Memorial Charitable Foundation, Marina Man-Wai Lee, the Hong Kong
256 Hainan Commercial Association South China Microbiology Research Fund, the Jessie &
257 George Ho Charitable Foundation, and Perfect Shape Medical Limited; and funding from the

258 Consultancy Service for Enhancing Laboratory Surveillance of Emerging Infectious Diseases
259 and Research Capability on Antimicrobial Resistance for Department of Health of the Hong
260 Kong Special Administrative Region Government; the Theme-Based Research Scheme
261 (T11/707/15) of the Research Grants Council; Hong Kong Special Administrative Region;
262 Sanming Project of Medicine in Shenzhen, China (No. SZSM201911014); and the High
263 Level-Hospital Program, Health Commission of Guangdong Province, China. The funding
264 sources had no role in the study design, data collection, analysis, interpretation, or writing of
265 the report.

266

267 References:

- 268 [1] Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a possible
269 cause of severe acute respiratory syndrome. *Lancet*. 2003; 361:1319-25.
- 270 [2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
271 infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020; 395:497-506.
- 272 [3] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses.
273 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-
274 nCoV and naming it SARS-CoV-2. *Nat Microbiol*. 2020; 5:536-544
- 275 [4] Worldometer.
276 https://www.worldometers.info/coronavirus/?utm_campaign=homeAdvegas1?%20
- 277 [5] Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
278 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
279 Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill*. 2020 Mar; 25(10): 2000180
- 280 [6] Chan KH, Peiris JSM, Lam SY, Poon LL, Yuen KY, Seto WH. The Effects of
281 Temperature and Relative Humidity on the Viability of the SARS Coronavirus. *Adv*
282 *Virology*. 2011; 2011:734690. doi: 10.1155/2011/734690
- 283 [7] Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the
284 2019 novel human-pathogenic coronavirus isolated from a patient with atypical
285 pneumonia after visiting Wuhan. *Emerg Microbes Infect*. 2020; 9:221-236.
- 286 [8] Reed LJ and Muench H. A simple method of estimating fifty percent end points.
287 *American Journal of Epidemiology*. 1938; 27:493-497.
- 288 [9] Darnell ME, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus
289 that induces severe acute respiratory syndrome, SARS-CoV. *J Virol Methods*. 2004
290 Oct;121(1):85-91.

- 291 [10] WHO Report, “First data on stability and resistance of SARS coronavirus compiled
292 b y
293 members of WHO laboratory network,” https://www.who.int/csr/sars/survival_2003_05_04/en/.
- 294 [11] Chu H, Chan JFW, Yuen TTT, Shuai H, Yuan S, Wang Y, et al. An observational study
295 on the comparative tropism, replication kinetics, and cell damage profiling of SARS-
296 CoV-2 and SARS-CoV: implications for clinical manifestations, transmissibility, and
297 laboratory studies of COVID-19. *The Lancet Microbe* 2020; May 1(1): e14–e23.
- 298 [12] Eleraky NZ, Potgieter LN, and Kennedy MA. Virucidal efficacy of four new
299 disinfectants. *J Am Anim Hosp Assoc.* 2002; 38:231-234.
- 300 [13] Chin AWH, Chu JTS, Perera MRA, Hui KPY, Hui PY, Yen HL, et al. Stability of
301 SARS-CoV-2 in different environmental conditions. *Lancet Micro.* Published online
302 April 2, 2020; [https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3).
- 303 [14] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN,
304 et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N*
305 *Engl J Med.* 2020; 382:1564-1567.
- 306 [15] Hindson J. COVID-19: faecal-oral transmission? *Nat Rev Gastroenterol Hepatol.* 2020
307 Mar 25. doi: 10.1038/s41575-020-0295-7.
- 308 [16] Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, et al. Gastrointestinal
309 Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the
310 Hong Kong Cohort and Systematic Review and Meta-analysis. *Gastroenterology* 2020,
311 Apr 3; S0016-5085(20)30448-0. doi: 10.1053/j.gastro. 2020.03. 065
- 312 [17] Dyal JW, Grant MP, Broadwater K, Bjork A, Waltenburg MA, Gibbins JD, et al.
313 COVID-19 Among Workers in Meat and Poultry Processing Facilities — 19 States,
314 April 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:557–561

Journal Pre-proof

316 Legends

317 Figure 1 Stability of SARS-CoV-2 and SARS-CoV-1

318 a) Stability of SARS-CoV-2 in dried form b) Stability of SARS-CoV-2 in solution

319 c) Stability of SARS-CoV-1 in dried form d) Stability of SARS-CoV-1 in solution

320

321 Table 1 Disinfectants used in the study

322 USA: United States of America

323 UK: United Kingdom

324 HKSAR: Hong Kong Special Administrative Region

325 HKU: University of Hong Kong

326 DMDM Hydantoin: 1,3-Bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione

327

328 Table 2 Effects of disinfectants on viability of SARS-CoV-2

329 * Include untreated virus stock solution as the viral load for the positive control

330 (TCID₅₀/ml = 6.50 ± 0.61).

331 All tests were neutralized before testing and was set up in triplicates.

332 Positive = Culture positive

333 Negative = Culture negative

334 ND = Not done

335

336

337 Table 3 Effects of different pH condition on infectivity of SARS-CoV-2

338 *Include untreated stock solution as the viral load for the positive control (TCID₅₀/ml

339 = 6.50±0.61). The experiment was set up in triplicate

340

Journal Pre-proof



341

342 Figure 1 Stability of SARS-CoV-2 and SARS-CoV-1

343

344 a) Stability of SARS-CoV-2 in dried form

b) Stability of SARS-CoV-2 in solution





345

346

347 c) Stability of SARS-CoV-1 in dried form

d) Stability of SARS-CoV-1 in solution



348

349 Table 1. Disinfectants used in the study

Disinfectant	Active ingredient	Supplier	Country or region
Ethanol (75%)	Ethanol 75%	VWR Chemicals BDH®	USA
Bleach (10%)	Sodium hypochlorite 10%,	Kao	Japan
Virkon (2%)	Potassium Peroxymonosulfate 21.41%, Sodium Chloride 1.5%	Lanxess	UK
Formalin (10%)	Formaldehyde 4%	Thermo fisher	USA
Lysis buffer (EasyMAG)	Guanidine thiocyanate 50%, Triton X-100 <2%, EDTA <1%	Biomerieux	France
AVL (viral lysis buffer)	Guanidine thiocyanate 50~70%	Qiagen	USA
Liquid hand soap	Biodegradable amphoteric surfactants and DMDM Hydantoin	Funchem	HKSAR
Hand wash	Sodium Laureth Sulfate, Cocamidopropyl betaine	Manning	China
Hand rub (WHO formula 1)	Ethanol 80% v/v, Glycerol 1.45% v/v, Hydrogen peroxide (H ₂ O ₂) 0.125% v/v	HKU in-house	HKSAR
Advanced hand sanitizer	Ethyl Alcohol 70%	Purell	USA
Disinfection solution	Sodium hypochlorite 0.002% and hypochlorous acid 0.013%	Dermo Dacyn	USA
Hand wash	Chloroxylenol (PCMX)	Walch	Germany

350 USA: United States of America

351 UK: United Kingdom

352 HKSAR: Hong Kong Special Administrative Region

353 HKU: University of Hong Kong

354 DMDM Hydantoin: 1,3-Bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione

355

356

357 Table 2 *Effects of different pH condition on infectivity of SARS-CoV-2

358

pH	Day 1 (Log ₁₀ Reduction ±SD)	Day 3 (Log ₁₀ Reduction ±SD)	Day 6 (Log ₁₀ Reduction ±SD)
2	Negative (6.50±0.00)	Negative (6.50±0.00)	ND
3	Negative (6.50±0.00)	Negative (6.50±0.00)	ND
4	Positive (2.67±0.29)	Negative (6.50±0.00)	Negative (6.50±0.00)
5	Positive (1.08±0.52)	Positive (2.33±0.29)	Positive (3.50±0.50)
6	Positive (1.00±0.50)	Positive (1.67±0.58)	Positive (4.10±0.85)
7	Positive (0.67±0.29)	Positive (1.50±0.50)	Positive (2.90±0.96)
8	Positive (1.23±0.25)	Positive (2.73±0.64)	Positive (3.92±0.63)
9	Positive (1.50±0.87)	Positive (3.23±0.68)	Positive (5.33±0.58)
10	Positive (2.40±0.36)	Positive (5.13±0.40)	Negative (6.50±0.00)
11	Positive (3.00±0.70)	Negative (6.50±0.00)	Negative (6.50±0.00)
12	Negative (6.50±0.00)	Negative (6.50±0.00)	ND
13	Negative (6.50±0.00)	Negative (6.50±0.00)	ND

359

360 * Untreated virus stock solution as the viral load for the positive control TCID₅₀/ml

361 =6.50±0.61. All tests were neutralized before testing and conducted in triplicates.

362 Positive = Culture positive

363 Negative = Culture negative

364 ND = Not done

365 Table 3 Effects of disinfectants on viability of SARS-CoV-2

366

Disinfectants*	Log ₁₀ reduction	
	1 min	5 min
Ethanol (75%)	$\geq 1.83 \pm 0.29$	$\geq 2.00 \pm 0.00$
Bleach (10%)	$\geq 3.25 \pm 0.00$	$\geq 3.25 \pm 0.00$
Virkon (2%)	$\geq 3.00 \pm 0.00$	$\geq 3.00 \pm 0.00$
Formalin (10%)	$\geq 1.25 \pm 0.00$	$\geq 1.25 \pm 0.00$
Lysis buffer (EasyMAG)	$\geq 2.00 \pm 0.43$	$\geq 2.25 \pm 0.00$
AVL (Viral lysis buffer, Qiagen)	$\geq 3.00 \pm 0.43$	$\geq 3.25 \pm 0.00$
Liquid hand soap (Funchem)	$\geq 2.00 \pm 1.56$	$\geq 2.25 \pm 0.00$
Hand wash (Mannings)	$\geq 0.83 \pm 0.29$	$\geq 0.92 \pm 0.38$
Hand rub (WHO Formulation 1)	$\geq 2.17 \pm 0.14$	$\geq 2.25 \pm 0.00$
Advanced hand sanitizer (Purell)	$\geq 2.50 \pm 0.0$	$\geq 2.50 \pm 0.0$
Disinfecting solution (Dermo docyn)	2.30 ± 0.50	3.75 ± 0.43
Hand wash (Walch)	$\geq 0.83 \pm 0.29$	$\geq 0.92 \pm 0.14$

367

368 *Untreated virus stock solution as the viral load for the positive control (TCID₅₀/ml =

369 6.50±0.61). The experiment was set up in triplicates.

370